Pharmacological activation of downregulated PGC-1α in NAFLD using various products can enhance neo-mitochondrial production, alleviate mitochondrial dysfunction, and improve NAFLD [634]. Here, PPARGC1A is linked to metabolic dysfunction-associated steatotic liver disease.